The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy.
 
Karim Saab
No Relationships to Disclose
 
Meghan Mooradian
No Relationships to Disclose
 
Daniel Ying Wang
No Relationships to Disclose
 
Jeewon Chon
No Relationships to Disclose
 
Cathy Yi Xia
No Relationships to Disclose
 
Angelica Bialczak
No Relationships to Disclose
 
Kelly Abbate
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Genoptix; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Ryan J. Sullivan
Honoraria - Roche/Genentech
Consulting or Advisory Role - ACI Clinical; Amgen; Array BioPharma; Biodesix; BiolineRx; Merck; Novartis; Takeda; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Other Relationship - Boehringer Ingelheim
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Castle Biosciences; Immunocore
Research Funding - Bristol-Myers Squibb; Immunocore; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb